List of Excipients in Branded Drug COMIRNATY

COMIRNATY Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

COMIRNATY uses a four-component lipid nanoparticle (LNP) system built around an ionizable lipid, PEG-lipid, phospholipid, and cholesterol. Its commercial value is concentrated in the LNP formulation, manufacturing process, analytical controls, and regulatory know-how rather than in conventional excipients such as sucrose or sodium chloride. The strongest opportunities are in lipid supply, high-purity raw materials, LNP process technology, stability improvement, analytical testing, and next-generation mRNA delivery systems.

What excipients are used in COMIRNATY?

COMIRNATY contains nucleoside-modified messenger RNA formulated in an LNP. The principal excipients are ALC-0315, ALC-0159, DSPC, cholesterol, sucrose, tromethamine, tromethamine hydrochloride, sodium chloride, and water for injection. The exact presentation and dose volume determine the final quantities listed in the applicable FDA labeling. [1]

COMIRNATY excipient composition

Component	Functional role	Commercial relevance
ALC-0315	Ionizable lipid; complexes with mRNA and supports endosomal escape	Highest-value proprietary excipient and major IP target
ALC-0159	PEG-lipid; controls particle size, aggregation, and circulation behavior	Important for particle stability and repeat-dose tolerability
DSPC	Structural phospholipid	Widely available, but pharmaceutical-grade supply and consistency matter
Cholesterol	Supports LNP membrane structure and packing	Commodity molecule with specialized pharmaceutical supply requirements
Sucrose	Cryo- and lyoprotective stabilizer	Supports frozen storage and particle integrity
Tromethamine	Buffer component	Controls formulation pH
Tromethamine hydrochloride	Buffer salt	Supports pH control and osmolality
Sodium chloride	Tonicity adjustment	Low-cost, non-differentiating excipient
Water for injection	Vehicle	Standard parenteral manufacturing input

The LNP excipients are not interchangeable in a simple formulation-development program. Changing the ionizable lipid, PEG-lipid, lipid ratio, particle size, or mRNA-to-lipid ratio can alter potency, biodistribution, reactogenicity, stability, and manufacturing performance.

How does the COMIRNATY LNP work?

The LNP protects mRNA from degradation and transports it into host cells. ALC-0315 is designed to remain relatively less charged at physiological pH but become protonated in acidic endosomal conditions. That charge transition helps disrupt the endosomal membrane and release mRNA into the cytoplasm.

ALC-0159 provides a PEG corona that limits aggregation during manufacture and storage. Excessive PEG-lipid content can reduce cellular uptake, while insufficient PEG-lipid can increase particle size and aggregation. DSPC and cholesterol provide structural organization and influence particle rigidity, encapsulation, and release.

The excipient strategy therefore has four linked objectives:

1. Preserve mRNA integrity.
2. Achieve high encapsulation efficiency.
3. Maintain an acceptable particle-size distribution.
4. Deliver sufficient intracellular mRNA while controlling reactogenicity.

The formulation is a system. A supplier that offers only one isolated lipid may have limited commercial value unless it can support the full LNP process and analytical package.

What formulation patents protect COMIRNATY?

COMIRNATY is protected by a layered IP estate rather than by one formulation patent. Relevant layers include:

• Nucleoside-modified mRNA composition and sequence claims.
• LNP composition claims covering ionizable lipids and lipid combinations.
• PEG-lipid, phospholipid, and cholesterol ratios.
• Encapsulation and particle-engineering methods.
• Manufacturing processes for mixing, purification, concentration, and sterile filtration.
• Stabilized liquid formulations and storage conditions.
• Methods of treating or preventing SARS-CoV-2 infection.
• Variant-specific or updated antigen sequences.

The commercial importance of ALC-0315 and ALC-0159 does not mean that every supplier of the same chemical can freely commercialize the materials for use in an infringing LNP. Patent exposure may arise from the chemical structure, method of manufacture, use in an LNP, or combination with mRNA.

Are the key COMIRNATY excipients generic or proprietary?

DSPC, cholesterol, sucrose, sodium chloride, and tromethamine are established pharmaceutical materials. ALC-0315 and ALC-0159 are specialized lipids associated with the COMIRNATY formulation and have greater differentiation.

The distinction is commercially important:

• Conventional excipients compete mainly on quality, capacity, regulatory documentation, and price.
• Ionizable and PEG-lipids compete on chemical purity, batch reproducibility, toxicology packages, process capability, and freedom to operate.
• LNP manufacturing platforms compete on scale, mixing technology, encapsulation efficiency, particle-size control, and comparability data.

When does COMIRNATY lose exclusivity?

COMIRNATY received FDA approval under Biologics License Application No. 125742 on August 23, 2021. As a reference biological product, it is governed by the Public Health Service Act rather than the small-molecule Hatch-Waxman framework. The reference-product exclusivity period is generally 12 years from first licensure, placing the nominal U.S. biologic exclusivity endpoint in August 2033. [2]

That date does not establish a single worldwide commercial-entry date. Separate considerations include:

• Patent expiration dates.
• Patent-term adjustment or extension.
• Pediatric exclusivity.
• Regulatory approval timing.
• Injunctions and litigation settlements.
• Country-specific patent rights.
• Manufacturing and regulatory readiness of a follow-on product.

COMIRNATY has no conventional Orange Book listing because it is a biologic. Relevant patent and exclusivity information is assessed through the FDA Purple Book, FDA biologics records, issued patents, patent-family databases, and court filings. [3]

How many patents cover COMIRNATY?

No reliable single number exists because the relevant estate includes patents owned or licensed by Pfizer, BioNTech, and third parties, with claims that may cover different components or activities. A meaningful analysis must separate:

IP category	Potential subject matter
mRNA	Modified nucleosides, untranslated regions, codon optimization, sequence design
LNP chemistry	Ionizable lipids, PEG-lipids, phospholipids, lipid combinations
Formulation	Ratios, buffers, stabilizers, particle size, encapsulation
Manufacturing	Mixing, purification, concentration, filtration, fill-finish
Use	Vaccination against COVID-19 and variant-specific indications
Third-party rights	LNP platform and lipid-delivery patents

The highest commercial risk is usually concentrated in blocking claims, not in the total patent count. A large estate with narrow, overlapping claims may present less risk than a smaller estate containing broad composition or manufacturing claims.

What is the Orange Book and FDA status of COMIRNATY?

COMIRNATY is FDA-approved as a COVID-19 vaccine for specified age groups and updated formulations. It is not an Orange Book-listed small molecule. The principal U.S. regulatory reference is the FDA-approved prescribing information and the biologics license record. [1, 2]

A follow-on developer cannot rely on the ordinary abbreviated new drug application route used for a conventional tablet or injectable small molecule. A biosimilar or interchangeable designation under section 351(k) is theoretically relevant to biological products, but a vaccine containing a different antigen sequence, updated strain composition, or materially different LNP may require a more complex regulatory strategy.

Is there biosimilar risk for COMIRNATY?

Traditional biosimilar risk is lower than generic-drug risk because:

• Vaccines are administered seasonally or periodically rather than continuously.
• The antigen sequence may change.
• LNP composition and manufacturing controls can be difficult to reproduce.
• Clinical immunogenicity and safety data may be needed for a changed product.
• The reference product has substantial biologic and formulation complexity.
• Intellectual-property barriers extend beyond the active mRNA sequence.

The practical threat is more likely to come from competing updated COVID-19 vaccines, alternative mRNA products, protein-based vaccines, and combination respiratory vaccines than from a simple COMIRNATY biosimilar.

What commercial opportunities exist in COMIRNATY excipients?

1. Pharmaceutical-grade ionizable lipids

ALC-0315 and similar ionizable lipids are the most strategically valuable excipient category. Suppliers can compete through:

• High-purity synthesis.
• Control of regioisomers and related impurities.
• Scalable production.
• Residual-solvent and elemental-impurity control.
• GMP documentation.
• Toxicology support.
• Supply continuity.
• Technology transfer to vaccine manufacturers.

The strongest opportunity is not necessarily direct supply of ALC-0315. Suppliers may develop non-infringing ionizable lipids with improved potency, lower reactogenicity, higher storage stability, or better tissue targeting.

2. PEG-lipid alternatives

PEG-lipids are useful but commercially constrained by concerns about anti-PEG antibodies, repeat-dose tolerability, and accelerated blood clearance. Opportunities include:

• Cleavable PEG-lipids.
• Shorter-chain or lower-PEG-density systems.
• Non-PEG steric stabilizers.
• Biodegradable alternatives.
• Lipids designed for repeat-dose administration.

These technologies are relevant to vaccines, cancer immunotherapy, protein replacement, and gene-editing delivery.

3. LNP manufacturing platforms

Manufacturing is a major commercial bottleneck. Suppliers can offer:

• Microfluidic mixing systems.
• Continuous LNP production.
• Inline particle-size monitoring.
• Encapsulation-efficiency analytics.
• Tangential-flow filtration.
• Concentration and buffer-exchange systems.
• Closed sterile filling.
• Single-use assemblies.

A platform that reduces batch variability or shortens scale-up can create more value than a low-cost excipient supplier.

4. Stabilization and storage

COMIRNATY relies on frozen storage and strict handling requirements. Excipient developers can pursue:

• Improved cryoprotectant systems.
• Less temperature-sensitive formulations.
• Higher-concentration presentations.
• Lyophilized mRNA-LNP products.
• Extended in-use stability.
• Prefilled syringe stability.
• Reduced dependence on ultra-cold logistics.

Sucrose is effective and established, but it is not highly differentiated. The opportunity lies in preserving LNP size, potency, and mRNA integrity under less restrictive conditions.

5. Analytical and quality-control services

LNP products require more complex testing than conventional injectables. Commercial opportunities include:

• mRNA identity and integrity.
• Encapsulation efficiency.
• Particle-size distribution.
• Polydispersity.
• Zeta potential.
• Lipid identity and degradation products.
• Residual solvents.
• Free mRNA quantification.
• Potency assays.
• Sterility and endotoxin testing.
• Container-closure compatibility.

Testing laboratories with validated methods and regulatory experience can become embedded in development and post-approval manufacturing networks.

Which companies are positioned in the COMIRNATY excipient market?

The competitive landscape includes several groups:

Company category	Representative participants	Opportunity
Vaccine sponsor	Pfizer and BioNTech	Product, formulation, manufacturing, and commercialization
Lipid and LNP specialists	Acuitas Therapeutics, Precision NanoSystems, CordenPharma, Evonik	Lipid design and LNP process development
Contract manufacturers	Thermo Fisher Scientific, Siegfried, Lonza and other CDMOs	GMP lipid, LNP, and fill-finish capacity
Lipid suppliers	Croda, Cayman Chemical and specialty chemical manufacturers	Research, development, and GMP-grade lipid supply
Analytical providers	Contract testing laboratories and CDMOs	Release testing and characterization
Competing vaccine developers	Moderna, Novavax, Sanofi, CSL/Seqirus and others	Alternative platforms and seasonal product competition

Commercial participation depends on qualification by the sponsor or a contract manufacturer. A chemically equivalent excipient may still fail qualification because of impurity profile, scale, documentation, or supply-chain risk.

What patent litigation affects COMIRNATY and LNP technology?

LNP patent disputes have involved major vaccine companies and third-party platform owners. Litigation involving Moderna, Pfizer, BioNTech, CureVac, Alnylam, Arbutus, and related patent holders has focused on lipid delivery, mRNA vaccines, and royalty rights. These proceedings create potential exposure for manufacturers that supply or use LNP components, even when the supplier is not named in the original action.

A supplier should assess:

• Whether the lipid structure is claimed.
• Whether the synthesis route is claimed.
• Whether use in an mRNA-LNP is claimed.
• Whether the customer receives a patent indemnity.
• Whether a license is needed in each jurisdiction.
• Whether a settlement includes royalty obligations or field restrictions.

Patent litigation can alter economics without stopping supply. A court may permit continued commercialization subject to royalties, a license, or a settlement.

How strong is the COMIRNATY excipient patent estate?

The estate is commercially strong because it combines formulation complexity with manufacturing know-how and biological-product exclusivity. Its strength varies by claim type:

• Conventional excipients have weak standalone patent protection.
• ALC-0315 and ALC-0159 have stronger differentiation, but validity and scope depend on specific patent claims.
• LNP combinations can be difficult to design around without changing performance.
• Manufacturing know-how may remain important after individual patents expire.
• Updated vaccine formulations can create new regulatory and technical barriers even when older claims weaken.

The most defensible assets are likely to be integrated packages covering lipid chemistry, particle manufacture, analytical release, and product performance.

What generic launch scenarios exist for COMIRNATY?

Scenario 1: Competing updated vaccines

This is the most immediate competitive scenario. Developers can launch products based on updated SARS-CoV-2 strains without copying the full COMIRNATY formulation. Competition would focus on efficacy, safety, supply reliability, public procurement, and physician or consumer preference.

Scenario 2: Follow-on mRNA vaccine

A follow-on product could use a different ionizable lipid, PEG-lipid, or manufacturing process. It would face comparability, immunogenicity, safety, and patent challenges.

Scenario 3: Non-mRNA replacement

Protein-subunit and other vaccine platforms can compete without reproducing the COMIRNATY LNP. Novavax’s protein-based approach illustrates this route. [4]

Scenario 4: Licensed or settlement-based entry

A competitor may enter through a license covering LNP technology or through a litigation settlement. Royalty economics would be central to product viability.

What revenue exposure does COMIRNATY create?

Pfizer reported approximately $11.2 billion in COMIRNATY revenue for 2023, followed by a sharp decline as demand normalized after the pandemic. [5] The commercial model has shifted from mass vaccination toward seasonal, risk-based, private-market, government, and institutional demand.

Excipient suppliers therefore face two different markets:

• A high-volume but volatile pandemic market.
• A lower-volume, recurring vaccine market with greater emphasis on capacity flexibility and inventory discipline.

The broader opportunity is platform reuse. LNP excipients qualified for COMIRNATY-related manufacturing can support oncology vaccines, infectious-disease vaccines, gene therapies, and gene-editing products. Qualification history may reduce development risk for new programs, although each product still requires product-specific comparability and regulatory justification.

How does COMIRNATY compare with competing COVID-19 vaccines?

Attribute	COMIRNATY	Moderna mRNA vaccine	Novavax protein vaccine
Platform	mRNA-LNP	mRNA-LNP	Recombinant protein with adjuvant
Core delivery system	ALC-0315/ALC-0159-based LNP	Proprietary LNP system	No mRNA LNP
Main excipient opportunity	Ionizable lipids, PEG-lipids, LNP manufacturing	Similar, with different lipid estate	Protein stabilization and adjuvant supply
Patent risk	mRNA, LNP, manufacturing, use	LNP, mRNA, manufacturing, use	Protein antigen, adjuvant, formulation
Biosimilar exposure	Limited and technically complex	Limited and technically complex	Conventional generic substitution is unlikely
Strategic barrier	Scale, regulatory history, LNP qualification	Scale, regulatory history, LNP qualification	Antigen and adjuvant manufacturing

Key Takeaways

• COMIRNATY’s principal excipient value is in its LNP system, not in sucrose, sodium chloride, or buffer salts.
• ALC-0315 and ALC-0159 are the most commercially differentiated formulation components.
• LNP manufacturing, analytical testing, and stabilization technologies offer larger opportunities than commodity excipient supply.
• COMIRNATY is a biologic and does not have a conventional Orange Book patent listing.
• FDA approval began on August 23, 2021, with nominal 12-year reference-product exclusivity extending to August 2033, subject to the applicable statutory framework.
• Generic substitution risk is limited. Competition is more likely from updated COVID-19 vaccines and alternative platforms.
• Patent exposure can arise from lipid structure, LNP combination, manufacturing process, and mRNA use.
• The most valuable supplier assets are GMP scale, impurity control, regulatory documentation, and freedom to operate.
• Revenue opportunities are shifting from pandemic-scale demand to recurring seasonal vaccination and broader LNP-platform applications.

FAQs About COMIRNATY Excipients and Commercial Strategy

Does COMIRNATY contain PEG?

Yes. COMIRNATY contains ALC-0159, a PEG-lipid used to stabilize the LNP and control particle behavior. [1]

Is ALC-0315 a conventional pharmaceutical excipient?

No. ALC-0315 is a specialized ionizable lipid used as a functional delivery component in the mRNA-LNP. It should be assessed for chemical purity, toxicology, manufacturing consistency, and patent position.

Can a company sell an ALC-0315 alternative?

Potentially, but chemical similarity does not establish freedom to operate. The alternative must be assessed against composition, process, formulation, and use claims in each relevant jurisdiction.

Does COMIRNATY require ultra-cold storage for every presentation?

Storage requirements depend on the approved presentation and formulation. FDA labeling specifies the applicable frozen, refrigerated, thawed, and handling conditions. [1]

Are COMIRNATY’s excipients suitable for other mRNA products?

They may provide a development starting point, but suitability is product-specific. Changes in mRNA sequence, dose, route, particle size, lipid ratio, and storage conditions can require new characterization and regulatory justification.

References

1. U.S. Food and Drug Administration. (2024). COMIRNATY prescribing information. https://www.fda.gov
2. U.S. Food and Drug Administration. (2021). FDA approves first COVID-19 vaccine. https://www.fda.gov
3. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
4. U.S. Food and Drug Administration. (2023). Novavax COVID-19 vaccine, adjuvanted. https://www.fda.gov
5. Pfizer Inc. (2024). 2023 annual review. https://www.pfizer.com/investor-relations/financial-information/annual-reports-and-proxy-statement